EpiVax Launches AI-Enhanced Models for Immunogenicity Prediction
PROVIDENCE, R.I., Sept. 2, 2026 /PRNewswire/ — EpiVax, Inc. is pleased to announce the release of AI-enabled enhancements to ISPRI™, its proprietary in silico platform for assessing the immunogenicity risk of biotherapeutics. The
